NCT00750893View on ClinicalTrials.gov

Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants

CompletedOBSERVATIONAL
Enrollment

3,111

Participants

Timeline

Start Date

September 2, 2008

Primary Completion Date

June 15, 2013

Study Completion Date

June 15, 2013

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

Rotarix or Rotarix liquid formulation

GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).

Trial Locations (1)

122-896

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY